Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Draft “Straw Man” Mobile Health App Guidance With Industry Help

This article was originally published in The Gray Sheet

Executive Summary

FDA intends to release draft guidance on mobile health applications later this year to help gather feedback as it creates a more comprehensive mHealth regulatory policy, but not without industry input.

You may also be interested in...



Cloud Computing Could Complicate Efforts To Clarify Mobile Health Regulation

Advances in cloud computing – where data storage or processing tasks for a software application are distributed among multiple remote computer networks – are adding a new wrinkle to industry’s efforts to draft a mobile health regulatory guidance document for FDA review.

Cloud Computing Could Complicate Efforts To Clarify Mobile Health Regulation

Advances in cloud computing – where data storage or processing tasks for a software application are distributed among multiple remote computer networks – are adding a new wrinkle to industry’s efforts to draft a mobile health regulatory guidance document for FDA review.

Mobile Health Start-Ups Encouraged To Band Together On Public Policy Advocacy

Start-up firms developing mobile health technologies must remember to budget resources for public policy advocacy in order to protect their business interests, according to an attorney speaking June 22 at a conference in New York City.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel